← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
CGTBiologicIstituto Clinico HumanitasPreclinical

immune evaluation (immune evaluation)

Oligorecurrent and Oligoprogressive Prostate Cancer Patients · Oligorecurrent and Oligoprogressive Pros

#OligorecurrentandOligoprogressiv#CGT#Preclinical#인기#세포유전치료+4
효능 ORR 37.5%임상시험 61상태 RECRUITING
CGTBiologicByron LamPhase 1

Higher (injection of scAAV2-P1ND4v2 1.0 X10e11vg, injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#인기#세포유전치료+3
효능 ORR 0.03%임상시험 61상태 ACTIVE
CGTBiologicByron LamPhase 1

injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low, injection of scAAV2-P1ND4v2 1.18x10e9 vg, injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),)

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#인기#세포유전치료+4
효능 ORR 2.53%임상시험 61상태 ACTIVE
CGTBiologicByron LamPhase 1

High (injection of scAAV2-P1ND4v2 2.4 X10e10vg, injection of scAAV2-P1ND4v2 2.4 X10e10vg (High))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#인기#세포유전치료+4
효능 ORR 0.03%임상시험 61상태 ACTIVE
CGTBiologicByron LamPhase 1

Med (injection of scAAV2-P1ND4v2 5.81 X10e9 vg, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#인기#세포유전치료+3
효능 ORR 73.59%임상시험 61상태 ACTIVE
ADCBiologicChipscreen Biosciences, Ltd.sPhase 3

taxane drug (taxane drug)

HER2-positive Metastatic Breast Cancer; First-line Treatment · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 81.1%임상시험 61상태 RECRUITING
CGTBiologicstaleGlaxoSmithKlineSN-38 also augmented IL-10 …Phase 2

topotecan hydrochloride (topotecan hydrochloride)

Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 95.4%임상시험 61상태 DISCONTINUED
AntibodystaleRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
CGTBiologicstaleSinobioway Cell Therapy Co., Lt…Preclinical

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
효능 ORR 94%임상시험 60상태 ACTIVE
AntibodystaleMario Negri Institute for Pharm…Approved

Certolizumab pegol (Certolizumab pegol)

Rheumatoid Arthritis · Crohn's Disease

#CrohnsDisease#Antibody#Approved#인기#항체+4
효능 ORR 5%임상시험 60상태 ACTIVE
CGTBiologicstaleEpicentRx, Inc.Phase 2

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

Solid Tumor, Adult; Cancer · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase2#인기#세포유전치료+5
효능 ORR 59%임상시험 60상태 RECRUITING
CGTBiologicstaleBellicum PharmaceuticalssPhase 2

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 80.3%임상시험 60상태 RECRUITING
CGTBiologicstaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 60상태 RECRUITING
CGTBiologicstaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 60상태 RECRUITING
AntibodystaleGlaxoSmithKlinederuxtecan improved objecti…Phase 2

Dostarlimab (Dostarlimab)

Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase2#인기#항체+5
효능 ORR 88%임상시험 60상태 DISCONTINUED
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 1

Gemcitabine/Cisplatin II (Gemcitabine/Cisplatin II)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 72%임상시험 60상태 ACTIVE
CGTBiologicstaleAmerican Gene Technologies Inte…sPreclinical

Gene modified therapy (Gene modified therapy)

HIV · HIV

#HIV#CGT#Preclinical#인기#세포유전치료+4
효능 ORR 41.6%임상시험 60상태 ACTIVE
CGTBiologicstaleNational Heart, Lung, and Blood…Phase 2

Haploidentical Hematopoietic Cell Transplantation (Haploidentical Hematopoietic Cell Transplantation)

Hemoglobinopathy (Disorder); Severe Aplastic Anemia · Primary Immune Deficiency Disorders

#PrimaryImmuneDeficiencyDisorders#CGT#Phase2#인기#세포유전치료+5
임상시험 60상태 RECRUITING
ADCBiologicAmgenPhase 2

Intensity-Modulated Radiotherapy (Intensity-Modulated Radiotherapy)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 74%임상시험 60상태 RECRUITING
CGTBiologicMalaysia Palm Oil BoardPhase 1

Interleukin (Interleukin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#인기#세포유전치료+3
효능 ORR 2%임상시험 60상태 ACTIVE

14 / 177 페이지

← 이전다음 →